COVID-19 press releases

After assessing safety and immunogenicity in phase 1/2 clinical trials, NVX-CoV2373 is currently in two pivotal phase 3 studies to evaluate vaccine efficacy, safety and immunogenicity.

NVX-CoV2373 clinical trials have enrolled more than 30,000 volunteers around the globe. Learn more about our clinical trial enrollment and progress toward diversity demographics.

Sep 12, 2023

Statement

COVID-19

U.S. CDC and Advisory Committee Recommend Use of Authorized and Approved 2023-2024 Monovalent XBB COVID-19 Vaccines

Read full article

Aug 22, 2023

COVID-19

Novavax's Updated Protein-based XBB COVID Vaccine Induced Neutralizing Responses Against Emerging Subvariants, Including EG.5.1 and XBB.1.16.6

Read full article

Jul 13, 2023

Statement

COVID-19

Novavax Intends to Deliver Protein-based XBB COVID Vaccine as Specified in U.S. HHS Letter to COVID Manufacturers

Read full article

Jul 6, 2023

COVID-19

Novavax's Nuvaxovid™ Receives Full Marketing Authorization in the EU for the Prevention of COVID

Read full article

Jun 15, 2023

COVID-19

Novavax Prepared to Deliver Protein-based Monovalent XBB COVID Vaccine Consistent with FDA VRBPAC Recommendation for the Fall

Read full article

May 26, 2023

COVID-19

Novavax's Nuvaxovid™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

Read full article

May 12, 2023

COVID-19

Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore

Read full article

May 9, 2023

COVID-19,Seasonal influenza

Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses

Read full article

Apr 4, 2023

COVID-19,Seasonal influenza

Novavax Grows Presence at World Vaccine Congress 2023 and 33rd European Congress of Clinical Microbiology & Infectious Diseases

Read full article

Feb 13, 2023

COVID-19

U.S. Government and Novavax Extend Partnership, Securing Up to 1.5 Million Additional Doses of Novavax' COVID-19 Vaccine

Read full article

Visit our global authorization website

Our commitment to equitable access and transparency

COVID-19 vaccine clinical trial

PREVENT-19 phase 3 data fact sheet

Estudio en fase 3 PREVENT-19 hoja de datos

Announcement of UK and South Africa trial results

Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial

PREVENT-19 fact sheet

Background information on PREVENT-19, Novavax pivotal phase 3 trial

Showper page